Biomarkers such as procalcitonin (PCT) can further guide prognosis of bacterial sepsis, assessment of mortality risk, and duration of antibiotic therapy. Join Stefan Riedel, MD, PhD, as he shares his working knowledge of the utility of procalcitonin and other biomarkers in diagnosing and managing sepsis and other bacterial infections, such as bacterial pneumonia. In this presentation Riedel will also explore analytical and clinical considerations of PCT.
WHAT YOU WILL LEARN:
- How to describe the biology & kinetics of procalcitonin and other biomarkers.
- How to compare the performance characteristics of procalcitonin assays dependent on various analytical testing platforms
- How to identify the utility of procalcitonin and other biomarkers to aid in the differential diagnosis of various infectious diseases, including bacterial sepsis and pneumonia
- How to assess the utility of procalcitonin and other biomarkers for management of bacterial infection with focus on antimicrobial stewardship
Stefan Riedel, MD, PhD, D(ABMM), FCAP
Associate Medical Director, Clinical Microbiology Laboratories
Beth Israel Deaconess Medical Center
Associate Professor of Pathology, Harvard Medical School
This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID# 2001. This activity was planned in accordance with ACCENT® Standards and Policies.